论文部分内容阅读
目的了解缺血性脑血管病二级预防中阿托伐他汀的应用情况。方法对动脉粥样硬化性脑梗死及短暂性缺血发作(TIA)患者479例及其出院6个月随访的422例,调查住院期间及出院6个月时阿托伐他汀的应用情况。结果住院期间,患者阿托伐他汀钙的使用率为41.5%,脑梗死与TIA患者的使用率无显著统计学差异(40.8%对40.3%,P=0.9411)。阿托伐他汀的使用率随基线LDL-C的增高而增高,但达标率呈下降趋势。出院6个月,阿托伐他汀的使用率、达标率分别降至28.7%和38.8%,与住院期间相比均明显降低(P=0.000,P=0.017)。结论缺血性脑血管病二级预防中,阿托伐他汀的使用率及达标率均较低,临床实践与指南尚有差距。
Objective To understand the application of atorvastatin in secondary prevention of ischemic cerebrovascular disease. Methods 479 patients with atherothrombotic cerebral infarction and transient ischemic attack (TIA) and 422 patients who were followed up for 6 months were investigated. The application of atorvastatin during hospitalization and 6 months after discharge was investigated. Results During hospitalization, the rate of using atorvastatin in patients was 41.5%. There was no statistically significant difference between the rates of cerebral infarction and TIA (40.8% vs. 40.3%, P = 0.9411). The use of atorvastatin increased with the increase of baseline LDL-C, but the compliance rate showed a decreasing trend. At 6 months after discharge, the rates of use and compliance of atorvastatin dropped to 28.7% and 38.8%, respectively, which were significantly lower than those during hospitalization (P = 0.000, P = 0.017). Conclusion Secondary prevention of ischemic cerebrovascular disease, atorvastatin use rate and compliance rates are low, there is still a gap between clinical practice and guidelines.